Review

Ethiopian Medicinal Plants Traditionally Used for the Treatment of Cancer, Part 2: A Review on Cytotoxic, Antiproliferative, and Antitumor Phytochemicals, and Future Perspective

Solomon Tesfaye 1,*, Kaleab Asres 1, Ermias Lulekal 2, Yonatan Alebachew 1, Eyael Tewelde 1, Mallika Kumarihamy 3 and Ilias Muhammad 3,*

1 School of Pharmacy, College of Health Sciences, Addis Ababa University, Churchill Street, 1176 Addis Ababa, Ethiopia; kaleab.asres@aau.edu.et (K.A.); yonalebachew@gmail.com (Y.A.); eyaelt@gmail.com (E.T.)
2 Department of Plant Biology and Biodiversity Management, College of Natural and Computational Sciences, The National Herbarium, Addis Ababa University, 34731 Addis Ababa, Ethiopia; ermias.lulekalm@aau.edu.et
3 National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA; mkumarih@olemiss.edu

* Correspondence: soltesfa2010@gmail.com (S.T.); milias@olemiss.edu (I.M.);
Tel.: +251-930-518-816 (S.T.); +1-662-915-1051 (I.M.)

Academic Editors: Clementina Manera and Derek J. McPhee
Received: 5 August 2020; Accepted: 2 September 2020; Published: 3 September 2020

Abstract: This review provides an overview on the active phytochemical constituents of medicinal plants that are traditionally used to manage cancer in Ethiopia. A total of 119 articles published between 1968 and 2020 have been reviewed, using scientific search engines such as ScienceDirect, PubMed, and Google Scholar. Twenty-seven medicinal plant species that belong to eighteen families are documented along with their botanical sources, potential active constituents, and in vitro and in vivo activities against various cancer cells. The review is compiled and discusses the potential anticancer, antiproliferative, and cytotoxic agents based on the types of secondary metabolites, such as terpenoids, phenolic compounds, alkaloids, steroids, and lignans. Among the anticancer secondary metabolites reported in this review, only few have been isolated from plants that are originated and collected in Ethiopia, and the majority of compounds are reported from plants belonging to different areas of the world. Thus, based on the available bioactivity reports, extensive and more elaborate ethnopharmacology-based bioassay-guided studies have to be conducted on selected traditionally claimed Ethiopian anticancer plants, which inherited from a unique and diverse landscape, with the aim of opening a way forward to conduct anticancer drug discovery program.

Keywords: medicinal plants; cancer; Ethiopia; phytochemistry

1. Introduction

Cancer is a major global health challenge that affects millions of people annually across the world. Recent estimates showed about 18.1 million new cases of cancer and 9.6 million cancer-related deaths worldwide [1]. Moreover, due to population growth, aging, and increased prevalence of key risk factors, this figure is expected to rise in the coming years. According to the same report, different from other parts of the world, cancer death (7.3%) is higher than cancer incidence (5.2%) in Africa. This is mainly attributed to lack of adequate health care facilities as well as professionals, lack of early cancer detection system, and poor access to chemotherapeutic treatments. Due to these and other
factors, including socio-economic conditions, the majority of the population of Africa has relied on traditionally used medicinal herbs and/or plants as a monotherapy or in combination with clinically approved anticancer drugs.

Medicinal plants have been a rich source of clinically effective anticancer agents for the past few decades. Over 60% of the currently used anticancer drugs are either directly derived from plants or inspired by their novel phytochemicals [2] and/or unique ligands as secondary metabolites. In spite of such success, the importance of medicinal plants as a source of leads for anticancer drug discovery was marginalized in comparison with other advanced approaches. This could be due to issues associated with intellectual property rights and securing not enough amounts of plant material which results in the slowness of working with natural products [3]. However, despite these drawbacks, medicinal plant-based drug discovery and development has made a comeback to find potent and affordable natural products with a new mechanism of action and better toxicological profile due to structural diversity of natural product small molecules (NPSM). For instance, among small molecules approved for cancer treatment between 1940 and 2014, 49% are derived and/or originated from natural products [4].

Ethiopia inherited a unique array of fascinating flora from its diverse landscape. Due to the geographical location and diversity, which favors the existence of different habitat and vegetation zones, Ethiopia is home to a variety of plant species. The Ethiopian flora is estimated to contain 6027 species of higher plants of which more than 10% are estimated to be endemic [5]. Different authors have compiled ethnobotanical and ethnopharmacological profiles and reviews of Ethiopian traditionally used medicinal plants [6,7]. However, published reports regarding isolated bioactive compounds of traditionally used Ethiopian medicinal plants, especially those with cytotoxic properties are scant. However, investigations conducted on plants with cytotoxic properties outside Ethiopia, include the study on Catha edulis Forsk [8,9], Artemisia annua L., Rumex abyssinicus Jacq. [9], Carissa spinarum L., Dodonaea angustifolia L.f., Jasminum abyssinicum Hochst. ex DC., Rumex nepalensis Spreng., Rubus steudneri Schweinf. and Verbascum sinaicum Benth. [10], Viola abyssinica Steud. ex Oliv. [11], Xanthium strumarium L. [12], Senna singueana (Del). Lock [13], Glinus lotoides L. [14], Kniphofia foliosa Hochst [15], Sideroxylon oxyacanthum Baill., Clematis simensis Fresen, and Dovyalis abyssinica (A. Rich) Warburg [16]. Thus, for further evaluation, identification, or modification of anticancer leads, thorough review of the chemistry and pharmacology of medicinal plants from relatively uncovered traditional medical systems is crucial. Therefore, in continuation of our previous mini-review [17], in which we documented both ethnobotanical and ethnopharmacological evidence of Ethiopian anticancer plants involving mostly the cytotoxic and antioxidant activities of crude extracts, here, in this review, we comprehensively document the cytotoxic and antiproliferative constituents from anticancer plants those traditionally used in Ethiopia. The secondary metabolites reported from each medicinal plant species are categorized based on the class of natural products they belong to.

2. Traditional Uses of Selected Plants

A total of 27 anticancer traditional medicinal plants that belong to 18 botanical families and 27 genera are identified in this review. The botanical families Euphorbiaceae and Cucurbitaceae were the most dominant, represented with 15% and 11% of the selected plant species, respectively (Figure 1). All of the reviewed plants have direct traditional uses for treating either ailments with cancer-like symptoms (determined by traditional practitioner) or for laboratory-confirmed cancer cases. Besides treating cancer, the plants selected in this review are also cited for their various traditional uses, including for the treatment of eczema, leprosy, rheumatism, gout, ringworm, diabetes, respiratory complaints, warts, hemorrhoid, syphilis, and skin diseases (Table 1). The output calls for the need for further phytochemical and pharmacological investigation giving priority to those plants which have been cited most for their use to treat cancer.
**Figure 1.** Major plant families (in %) of reviewed plants species vegetation zone of Ethiopia [18] (the unmarked blocks are other species).

**Table 1.** General traditional use of selected Ethiopian medicinal plants.

| Botanical Name (Family) | Illnesses/Symptoms Claimed to Be Treated Traditionally |
|-------------------------|--------------------------------------------------------|
| *Bersama abysinica* (Fresen. (Melianthaceae)) | Antispasmodic [19]; tumor [20] |
| *Carissa spinarum* (Apocynaceae) | Skin cancer [21] |
| *Catharanthus roseus* (L.) G. Don (Apocynaceae) | Cancer, liver infection, Wound, rheumatism [22] |
| *Centella asiatica* (L.) Urb. (Apticaceae) | Genital infection [23]; gastritis, evil eye, swelling [24]; Throat cancer [21] |
| *Croton macrostachyus* Hochst. Ex Delile (Euphorbiaceae) | Stomach ache, typhoid, worm expulsion, wounds, malaria [25]; wounds, malaria and gonorrhea [26]; tumor [27]; skin cancer, wound, ring worm [28]; cancer [29] |
| *Cucumis prophetarum* (Cucurbitaceae) | Skin cancer, cough, stomach-ache, diarrhoea [30]; wound, swollen body part [7] |
| *Ekebergia capensis* Spar. (Meliaceae) | Weight loss in children, stabbing pain, bovine tuberculosis [29]; cancer [6] |
| *Euphorbia tirucalli* L. (Euphorbiaceae) | Tumors [27]; wart, wounds [31] |
| *Ferula communis* L. (Apticaceae) | Gonorrhea [32]; Lung cancer [33] |
| *Gloriosa superba* (Colchicaceae) | Snake bite, impotence, stomach-ache [34]; tumors [35] |
| *Jatropha curcas* L. (Euphorbiaceae) | Abdominal pain [36]; rables [25]; tumor [27,37] |
| *Juncus effusus* L. (Juncaceae) | Wound, stomach ache, bleeding after delivery, muscle cramps, tumors [27] |
| *Kauapha foliosa* Hochst (Asphodelaceae) | Cervical cancer [21] |
| *Lagenaria siceraria* (Molina) Standl. (Cucurbitaceae) | Diarrhea, vomiting [38]; gonorrhea [39]; wound [25]; cough, cancer [28] |
| *Linum usitatissimum* (Linaceae) | Gastritis [40,41] |
| *Maytenus senegalensis* (Celastraceae) | Stomach-ache [42]; snake bite, tonsillitis, diarrhoea [43]; tumors [20] |
| *Olea europaea* subsp. *Cuspidate* (Wall. ex. G. Don) Cif. (Oleaceae) | Stomach problems, malaria, dysentery [64]; Eye disease [45]; wound [46]; brain tumor [47] |
| *Plumbago zeypulica* L. (Plumbaginaceae) | Cancer [26]; external body swelling, internal cancer, bone cancer [7]; cancer, cough, snake bite, swelling [31] |
| *Podocarpus falcatus* (Podocarpaceae) | Cancer [34]; amoeba, gastritis [6]; rables [48] |
| *Premna schimperi* Engl. (Verbenaceae) | Antiseptic [49]; cancer [35] |
| *Prunus africana* (Hook.f.) Kalkman (Rosaceae) | Breast cancer [21]; benign prostatic hyperplasia, prostate gland hypertrophy [26] |
| *Ricinus communis* L. (Euphorbiaceae) | Rabies [48]; dysentery [50]; stomach ache [54,51]; Liver disease [52]; tooth ache [51]; breast cancer [28] |
| *Solanum nigrum* (Solanaceae) | Painful and expanding swelling on finger [7]; cancer [27] |
| *Vernonia amygdalina* Delile (Asteraceae) | Tonsillitis [34]; cancer [6] |
| *Vernonia hymenolepis* A. Rich. (Asteraceae) | Tumor [6,40,41] |
| *Withania somnifera* (Solanaceae) | Snake bite [53]; chest pain [34]; cancer [27] |
| *Zehneria scabra* (L.F. Sond) (Cucurbitaceae) | Fever, head ache [55]; tumor [56]; eye disease, wart [45] |
3. Phytochemistry of Ethiopian Anticancer Plants

The present review reports secondary metabolites isolated from 27 plants that are traditionally used to treat different types of cancer in Ethiopia. Phytochemical investigations of traditionally used Ethiopian anticancer plants have led to the isolation of compounds that belong to different classes of natural products [10,57]. In this review, we have not included plants those displayed compounds with very low cytotoxic/antiproliferative activity (i.e., IC_{50} (Concentration that inhibited cell proliferation by 50%)/ED_{50} (Effective dose for 50% of the population) > 50 µg/mL or > 100 µM, in most cases, except few where compounds tested against a panel of cell lines) or plants from which no anticancer compounds were isolated/reported. This review compiled and discussed the potential anticancer/antiproliferative agents based on the types of secondary metabolites, such as terpenoids, phenolic compounds, alkaloids, steroids, and lignans.

3.1. Terpenoids

Terpenoids are classified according to the number of their isoprene unit as hemi-, mono-, di-, tri-, tetra-, and polyterpenes [58]. Various studies reported that the anticancer activity of terpenoids is due to the inhibition of inflammation, cancer cell proliferation, angiogenesis and metastasis, and induction of programmed cell death [59]. Triterpenoids are one important class of terpenoids, which contain isopentenyl pyrophosphate oligomers [60]. They are biosynthesized by plants through cyclization of 30-carbon intermediate squalene and include various structural subclasses [61]. Several triterpenoids have been shown to have anticancer activity.

Among the different types of triterpenoids, pentacyclic triterpenoids display the most potent anti-inflammatory and anticancer activity [62]. Addo et al. [63] reported the isolation of two new nagilactones along with seven known from the root of Podocarpus falcatus (Thunb.) collected from Berga forest, Addis Alem, central Ethiopia. P. falcatus traditionally used to treat jaundice, gastritis, and amoeba [6]. Among the isolated compounds 16-hydroxynagilactone F (1), 2β,16-dihydroxy nagilactone F (2), 7β-hydroxymacrophyllic acid, nagilactone D (3), 15-hydroxynagilactone (4), and nagilactone I (5) (Figure 2) showed potent antiproliferative activity against HT-29 cell line (IC_{50} < 10 µM) (Table 2). Premna schimperi, another traditionally used Ethiopian plant, also showed cytotoxic activity against L929, RAW264.7, and SK.N.SH with IC_{50} values of 11 ± 2.3, 10 ± 2.3, and 1.5 ± 0.3 µg/mL, respectively [57]. The methanolic extract of another commonly used Ethiopian plant, Croton macrostachyus, was also shown to possess cytotoxic activity against HTCl16 cell line [64]. A diterpenoid compound methyl 2-(furan-3-yl)-6β,10β-dimethyl-l4-oxo-2,4,4α,5,6,6α,10α,10β-octahydro-1H-benzo[f]isochromene-7-carboxylate (6), demonstrated a moderate cytotoxic activity (IC_{50} = 50 µg/mL). The compound was shown to trigger caspase mediated apoptotic cell death. 3β-Hydroxy lup-20(9)-ene-27,28-dioic acid dimethyl ester (7), isolated from root of Plumbago zeylanica collected from India, also exhibited anti-proliferative and anti-migration activity against triple-negative breast cancer cell lines at IC_{50} value of 5 µg/mL [65].

Several terpenoids have been isolated from Ethiopian plants that have claims of having anticancer activity, although these plants may have been collected from other sources. For example, sonhafouonic acid (8) from Zebrina scabra, collected from Cameroon, demonstrated potent cytotoxicity against brine shrimp assay [66], while Lin et al. [67] showed the antiproliferative activity of euphol (9), isolated from Euphorbia tirucalli from Taiwan against human gastric cancer cells. Euphol selectively promotes apoptosis by mitochondrial-dependent caspase-3 activation and growth arrest through induction of p27kip1 and inhibition of cyclin B1 in human gastric CS12 cancer cells. It also showed a selective and strong cytotoxicity against other groups of human cancer cell lines such as glioblastoma (the most frequent and aggressive type of brain tumor) [67,68]. The molecular mechanism of action of another anticancer triterpenoid, maslinic acid (10), isolated from the leaves of Olea europaea has been studied, which induced apoptosis in HT29 human colon cancer cells by directly inhibiting the expression of Bcl-2, increasing that of Bax, releasing cytochrome-C from the mitochondria and activating caspase-9 and then caspase-3 [69]. Similarly, the leaf extract of Ricinus communis collected from Malta was also reported for its cytotoxicity against several human tumor cells and induction of apoptosis against...
human breast tumors, SK-MEL-28. The monoterpenoids 1,8-cineole, camphor and α-pinene, and the sesquiterpenoid β-caryophyllene, isolated from *R. communis*, also showed cytotoxicity against similar cell lines in a dose-dependent manner [70].

Figure 2. Cont.
Asiatic acid (19)          R 
Cucurbitacin E (20)            OH 
Cucurbitacin E glucoside (23)   Glucose 
Iso Cucurbitacin D (24) 

Figure 2. Structures of anticancer terpenoids reported from plants available in Ethiopia.

3.2. Phenolic Compounds
Phenolic compounds are biosynthesized by plants through shikimate, phenylpropanoid, and flavonoid pathways, and have an aromatic ring bearing one or more hydroxyl groups. These compounds have been reported for their antioxidant, antiproliferative, and cytotoxic properties [78]. Many phenolic compounds have been identified elsewhere from the same medicinal plants that are traditionally used to manage cancer in Ethiopia. For instance, (−)-epigallocatechin (25) isolated from Maytenus senegalensis has showed potent cytotoxic activity against mouse lymphoma cell line (L5178Y) [79]. Likewise, a series phenanthrenes (5-(1-methoxyethyl)-1-methyl-phenanthren-2,7-diol (26); effususol A; effusol; dehydroeffusol; dehydroeffusal; 2,7-dihydroxy-1,8-dimethyl-5-vinyl-9,10-dihydrophenanthrene and juncusol; dehydrojuncusol and 1-methylpyrene-2,7-diol) from Juncus effuses inhibited the proliferation of five human cancer cell lines (Table 3). Among these, 5-(1-methoxyethyl)-1-methyl-phenanthren-2,7-diol (26) (Figure 3) was tested against MCF-7 cancer cell line and showed better cytotoxic activity [80] than all isolated compounds from J. effuses. Another group of phenanthrenoids (effususol A, 27) has also demonstrated potent cytotoxicity against HT-22 cell by inducing caspase-3-mediated apoptosis [81]. Plumbagin (28), a naphthoquinone isolated from Plumbago zeylanica also induced apoptosis in human non-small cell lung (IC50 = 6.1–10.3 µM) [82] and human pancreatic (IC50 = 2.1 µM) [83] cancer cell lines. On the other hand, knipholone (29) isolated from Kniphofia foliosa Hochst collected from Ethiopia, induced necrotic death in mouse melanoma (B16), mouse macrophage tumor (RAW 264.7), human acute monocytic (THP-1), and promonocytic leukaemic (U937) cell lines with IC50 values that range from 0.5 ± 0.05 to 3.3 ± 0.39 µM [15].

Jatropha curcas is a medicinal plant traditionally used to treat a variety of ailments in different parts of the world including Ethiopia [71]. Investigation of J. curcas, collected from China, resulted in the isolation of twelve phorbol esters (diterpenoids) including jatrophalactone (11), curcusecon A–J, 4-epi-curcusecon E, curcusone E, 3-dehydroxy-2-epi-caniojane (12), curcusone A (13), curcusone B (14), curcusone C (15), curcusone D (16), jatrogroside, 2-epi-jatrogrossidone, and 4E-jatrogrossidentadion (17) [72]. Most of these compounds showed potent cytotoxicity with IC50 values ranging from 0.084 to 20.6 µM against HL-60, SMMC-7721, A-549, MCF-7, SW480, and HEPG2 cell lines [72,73]. The pentacyclic triterpenoid oleanonic acid (18), isolated from Ekebergia capensis [74], exhibited potent cytotoxic activity against human epithelial type 2 (HEp2) and murine mammary carcinoma (4T1) cell with IC50 values of 1.4 and 13.3 µM, respectively. Another pentacyclic triterpenoid, asiatic acid (19), isolated from Centella asiatica, also showed 80% growth inhibition of human colorectal (SW480), human stomach (SNU668), and murine colorectal adenocarcinoma (CT26) cell lines with IC50 values of 20 µg/mL [75]. The fresh fruit of Cucumis prophetarum from Saudi Arabia yielded a series of cucurbitacin and analogs (cucurbitacin E (20), cucurbitacin B (21), cucurbitacin D (22), cucurbitacin F 25-O-acetate, cucurbitacin E glucoside (23), dihydrocurcurbitacin D, hexanor-cucurbitacin D, and isocucurbitacin D (24)), of which compounds 20–24 showed cytotoxic activity against MCF-7, MDA MB 231, A2780, A2780 CP, HepG2, and HCT-116 with IC50 values ranging from 1 to 27.3 µM [76].
### Table 2. Terpenoids isolated from medicinal plants that are traditionally used to treat cancer in Ethiopia.

| Plant Family               | Class of Compounds | Cell Lines | IC<sub>50</sub> | Pharmacology                        | Isolated Active Compounds                                                                 | Reference |
|----------------------------|--------------------|------------|----------------|-------------------------------------|------------------------------------------------------------------------------------------|-----------|
| *Ferula communis* L. (Apiaceae) | Daucane Sesquiterpene | Jurkat T-cells | - | Ionotropism | Ferutinin [34] | [34] |
| *Vernonia amygdalina* Delile (Asteraceae) | Sesquiterpene lactones | KB | - | - | Vernodalin and Vernomygdin [77] | [77] |
| *Vernonia hymenolepis* A. Rich. (Asteraceae) | Sesquiterpene Dilactone | - | - | - | Vernolepin | [77] |
| *Zehneria scabra* (L.F. Sond) (Cucurbitaceae) | Triterpoid | Brine shrimp | 10 µg/mL | - | Sonhafouonicacid (8) [66] | [66] |
| *Croton macrostachyus* Hochst. ex Delile* (Euphorbiaceae) | Diterpoid | HCT116 | 50 µg/mL | Caspase mediated apoptosis | methyl 2-(furan-3-yl)-6α,10β-dimethyl-14-oxo-2,4,4α,5,6,6α,10α,10β-octahydro-1H-benzo[f]isochromene-7-carboxylate) [64] | [64] |
| *Euphorbia tirucalli* L. (Euphorbiaceae) | Triterpoid | CS12 | 12.8 µg/mL | Apoptosis | Euphol (9) [67] | [67] |
| | | AGS | 14.7 µg/mL | | | |
| | | MKN45 | 14.4 µg/mL | | | |
| *Ricinus communis* L. (Euphorbiaceae) | Monoterpoid | SK-MEL-28 | 21.67 ± 4.74 µg/mL | | | |
| | | K-562 | 24.49 ± 1.61 µg/mL | | | |
| | | COLO 679 | 20.14 ± 2.99 µg/mL | | | |
| | | OAW42 | 13.52 ± 0.20 µg/mL | | | |
| | | HT-29 | 19.86 ± 5.94 µg/mL | | | |
| | | MCF-7 | 37.87 ± 3.36 µg/mL | | | |
| | | PBMC | 13.55 ± 0.85 µg/mL | | | |
| | | HL-60 | 8.5 µM | | Jatropha lactone (11) | |
| | | SMMC-7721 | 20.6 µM | | | |
| | | A-549 | 19.7 µM | | | |
| | | MCF-7 | 20.1 µM | | | |
| | | SW480 | 19.2 µM | | | |
| | | HL-60 | >40 µM | | | |
| *Jatropha curcas* L. (Euphorbiaceae) | Diterpoid | SMMC-7721 | >40 µM | | | |
| | | A-549 | >40 µM | | Curcuseon A-J, 4-epi-curcuseon E, Curcusone E [72] | |
| | | MCF-7 | >40 µM | | | |
| | | SW480 | >40 µM | | | |
| | | HL-60 | 2.86 µM | | 3-Dehydroxy-2-epi-Camiojane (12) | |
| | | SMMC-7721 | 3.94 µM | | | |
| | | A-549 | 3.49 µM | | | |
| | | MCF-7 | 11.69 µM | | | |
| | | SW480 | 14.05 µM | | | |
| Plant Family | Class of Compounds | Cell Lines | IC_{50} | Pharmacology | Isolated Active Compounds | Reference |
|--------------|--------------------|------------|--------|--------------|--------------------------|-----------|
| *Jatropha curcas* L. (Euphorbiaceae) | Diterpenoid | HL-60 | 1.63 μM | | | |
| | | SMMC-7721 | 3.10 μM | | | |
| | | A-549 | 3.35 μM | | | |
| | | MCF-7 | 2.47 μM | | | Curcusone A (13) |
| | | SW480 | 2.10 μM | | | |
| | | HL-60 | 2.64 μM | | | |
| | | SMMC-7721 | 3.30 μM | | | Curcusone B (14) |
| | | A-549 | 3.88 μM | | | |
| | | MCF-7 | 3.14 μM | | | |
| | | SW480 | 2.91 μM | | | |
| | | HL-60 | 1.36 μM | | | |
| | | SMMC-7721 | 2.17 μM | | | Curcusone C (15) |
| | | A-549 | 3.88 μM | | | |
| | | MCF-7 | 1.61 μM | | | [72] |
| | | SW480 | 1.99 μM | | | |
| | | HL-60 | 2.81 μM | | | |
| | | SMMC-7721 | 3.58 μM | | | Curcusone D (16) |
| | | A-549 | 4.70 μM | | | |
| | | MCF-7 | 2.77 μM | | | |
| | | SW480 | 2.83 μM | | | |
| | | HL-60 | 22.80 μM | | | |
| | | SMMC-7721 | 19.49 μM | | | Jatrogrisidone |
| | | A-549 | 34.93 μM | | | |
| | | MCF-7 | 21.83 μM | | | |
| | | SW480 | 20.06 μM | | | |
| | | HL-60 | 23.30 μM | | | |
| | | SMMC-7721 | 18.36 μM | | | 2-epi-Jatrogrissidone |
| | | A-549 | 36.53 μM | | | |
| | | MCF-7 | 22.72 μM | | | |
| | | SW480 | 21.08 μM | | | |
Table 2. Cont.

| Plant Family                      | Class of Compounds | Cell Lines       | IC_{50}     | Pharmacology               | Isolated Active Compounds | Reference |
|-----------------------------------|--------------------|------------------|-------------|---------------------------|---------------------------|-----------|
| *Jatropha curcas* L. (Euphorbiaceae) | Diterpenoid        | HEPG2            | 0.084 µM    |                           | Curcusone C (15)          | [73]      |
|                                   |                    |                  | 0.153 µM    |                           | Curcusone D (16)          |           |
|                                   |                    |                  | 0.183 µM    |                           | 4E-Jatrogrossidentadion   |           |
| *Premna schimperi* Engl.* (Verbenaceae) | Clerodane diterpene | L929             | 11 ± 2.3 µg/mL |                           | (5R,8R,9S,11OR)-12-Oxo-ent-3,13(16)-clerodjen-15-oic acid | [57]      |
| *Ekebergia capensis* Sparrm. (Meliaceae) | Triterpenoids      | HEP2             | 1.4 µM      |                           | Oleaninic acid (18)       | [74]      |
| *Olea europaea* subsp. Caspoidata (Wall. ex. G. Don) Cif. (Oleaceae) | Triterpenoids      | HT-29            | 28.8 ± 0.9 µg/mL | Apoptosis                 | Maslinic acid (18)        | [69]      |
|                                   |                    |                  | >10 µM       |                           | 16-Hydroxynagilactone F (1) |           |
| *Podocarpus falcatus* (Podocarpaceae) | Terpenoids-Nagilactones (diterpenoids) | HT-29 | 0.6 ± 0.4 µM |                           | 2β,16-Dihydroxynagilactone F (2) |           |
|                                   |                    |                  | 1.1 ± 0.5 µM |                           | 2β-Hydroxynagilactone F   |           |
|                                   |                    |                  | 0.3 ± 0.1 µM |                           | 7β-Hydroxymacrophyllic acid |           |
|                                   |                    |                  | >10 µM       |                           | Macrophyllic acid         |           |
|                                   |                    |                  | >10 µM       |                           | Nagilactone D (3)         |           |
|                                   |                    |                  | 0.9 ± 0.3 µM |                           | Nagilactone I (5)         |           |
|                                   |                    |                  | 5.1 ± 0.8 µM |                           | Inumakiol D               |           |
|                                   |                    |                  | 0.5 ± 0.1 µM |                           | Ponasterone A             |           |
| *Cucumis prophetarum* (Cucurbitaceae) | Triterpenoids      | MCF-7            | 7.2 µM      |                           | Cucurbitacin E (20)       | [76]      |
|                                   |                    |                  |              |                           |                           |           |
|                                   |                    |                  | 2.1 µM      |                           |                           |           |
|                                   |                    |                  | 5.4 µM      |                           |                           |           |
|                                   |                    |                  | 15.9 µM     |                           |                           |           |
|                                   |                    |                  | 3.4 µM      |                           |                           |           |
|                                   |                    |                  | 3.4 µM      |                           |                           |           |
Table 2. Cont.

| Plant Family                | Class of Compounds | Cell Lines | IC\textsubscript{50} | Pharmacology | Isolated Active Compounds                  | Reference |
|-----------------------------|--------------------|------------|----------------------|--------------|-------------------------------------------|-----------|
| *Cucumis prophetarum* (Cucurbitaceae) | Triterpenoids       | MCF-7      | 16.0 µM              |              |                                          |           |
|                             |                    | MDA MB 231 | 0.96 µM              |              | Cucurbitacin B (21)                     |           |
|                             |                    | A2780      | 7.6 µM               |              |                                          |           |
|                             |                    | A2780 CP   | 14.2 µM              |              |                                          |           |
|                             |                    | HepG2      | 1.7 µM               |              |                                          |           |
|                             |                    | HCT-116    | 3.1 µM               |              |                                          |           |
|                             |                    | MCF-7      | 47.9 µM              |              |                                          |           |
|                             |                    | MDA MB 231 | 12.0 µM              |              | Hexanor-Cucurbitacin D                  |           |
|                             |                    | A2780      | >100 µM              |              |                                          |           |
|                             |                    | A2780 CP   | >100 µM              |              |                                          |           |
|                             |                    | HepG2      | 37.8 µM              |              |                                          |           |
|                             |                    | HCT-116    | 30.7 µM              |              |                                          |           |
| *Cucumis prophetarum* (Cucurbitaceae) | Triterpenoids       | MCF-7      | 26.7 µM              |              |                                          | [76]      |
|                             |                    | MDA MB 231 | 4.0 µM               |              |                                          |           |
|                             |                    | A2780      | 21.6 µM              |              | Cucurbitacin D (22)                     |           |
|                             |                    | A2780 CP   | 6.9 µM               |              |                                          |           |
|                             |                    | HepG2      | 5.0 µM               |              |                                          |           |
|                             |                    | HCT-116    | 7.6 µM               |              |                                          |           |
|                             |                    | MCF-7      | 18.4 µM              |              |                                          |           |
|                             |                    | MDA MB 231 | 3.4 µM               |              | Cucurbitacin F 25-O-acetate            |           |
|                             |                    | A2780      | 15.8 µM              |              |                                          |           |
|                             |                    | A2780 CP   | 15.2 µM              |              |                                          |           |
|                             |                    | HepG2      | 10.2 µM              |              |                                          |           |
|                             |                    | HCT-116    | 11.2 µM              |              |                                          |           |
|                             |                    | MDA MB 231 | >100 µM              |              | Dihydrocucurbitacin D                   |           |
|                             |                    | A2780      | 27.3 µM              |              | Cucurbitacin E glucoside (23)           |           |
|                             |                    | A2780 CP   | 1 µM                 |              | Isocucurbitacin D (24)                  |           |
Table 2. Cont.

| Plant Family     | Class of Compounds | Cell Lines | IC\textsubscript{50}         | Pharmacology                     | Isolated Active Compounds       | Reference |
|------------------|--------------------|------------|-------------------------------|----------------------------------|---------------------------------|-----------|
| Centella asiatica| Triterpenoids      | SW480      | 20 µg/mL (80% growth inhibition) | Growth inhibition and apoptosis   | Asiatic Acid (19)               | [75]      |
|                  |                    | SNU668     |                               |                                   |                                 |           |
|                  |                    | CT26       |                               |                                   |                                 |           |
| Plumbago zeylanica| Triterpenoids      | MDA-MB-231 | 5 µg/mL                       | Inhibits proliferation and migration | 3β-Hydroxylup-20(29)-ene-27,28-dioic acid (7) | [65]      |

Cell lines: HCT116 = Human colorectal carcinoma, CS12 = Human gastric carcinoma, AGS = Human gastric carcinoma, MKN-45 = Human gastric adenocarcinoma, SK-MEL-28 = Human melanoma, K562 = Human myelogenous leukemia, COLO 679 = Human melanoma, OAW42 = Human ovarian carcinoma, HT-29 = Human colorectal adenocarcinoma, MCF-7 = Human breast adenocarcinoma, PBMC = Peripheral blood mononuclear, HL-60 = Human promyelocytic leukemia, SMMC-7721 = Human hepatocarcinoma, A-549 = Human lung adenocarcinoma, SW480 = Human colorectal, HepG2 = Liver hepatocarcinoma, L929 = Murine fibroblast, RAW264.7 = murine macrophage, SK.N.SH = Human neuroblastoma, HEp-2 = Human epithelial type 2, 4T1 = Murine mammary carcinoma, HT-29 = Human colorectal adenocarcinoma, Caco-2 = Human colon carcinoma, MDA MB 231 = Triple-negative breast cancer, A2780 = Human ovarian carcinoma, A2780 CP = cisplatin-resistant ovarian carcinoma, HCT116 = Human colorectal carcinoma. IC\textsubscript{50} = Concentration that inhibited cell proliferation by 50%. * Plant material collected from Ethiopi.
3.2. Phenolic Compounds

Phenolic compounds are biosynthesized by plants through shikimate, phenylpropanoid, and flavonoid pathways, and have an aromatic ring bearing one or more hydroxyl groups. These compounds have been reported for their antioxidant, antiproliferative, and cytotoxic properties [78]. Many phenolic compounds have been identified elsewhere from the same medicinal plants that are traditionally used to manage cancer in Ethiopia. For instance, (−)-epigallocatechin (25) isolated from *Maytenus senegalensis* has showed potent cytotoxic activity against mouse lymphoma cell line (L5178Y) [79]. Likewise, a series phenanthrenes (5-(1-methoxyethyl)-1-methyl-phenanthren-2,7-diol (26); effususol A; effusol; dehydroeffusol; dehydroeffusol; 2,7-dihydroxy-1,8-dimethyl-5-vinyl-9,10-dihydrophenanthrene and juncusol; dehydrojuncusol and 1-methylpyrene-2,7-diol) from *Juncus effusus* inhibited the proliferation of five human cancer cell lines (Table 3). Among these, 5-(1-methoxyethyl)-1-methyl-phenanthren-2,7-diol (26) (Figure 3) was tested against MCF-7 cancer cell line and showed better cytotoxic activity [80] than all isolated compounds from *J. effusus*. Another group of phenanthrenoids (effususol A, 27) has also demonstrated potent cytotoxicity against HT-22 cell by inducing caspase-3-mediated apoptosis [81]. Plumbagin (28), a naphthoquinone isolated from *Plumbago zeylanica* also induced apoptosis in human non-small cell lung (IC₅₀ = 6.1–10.3 µM) [82] and human pancreatic (IC₅₀ = 2.1 µM) [83] cancer cell lines. On the other hand, knipholone (29) isolated from *Kniphofia foliosa* Hochst collected from Ethiopia, induced necrotic death in mouse melanoma (B16), mouse macrophage tumor (RAW 264.7), human acute monocytic (THP-1), and promonocytic leukaemic (U937) cell lines with IC₅₀ values that range from 0.5 ± 0.05 to 3.3 ± 0.39 µM [15].

![Figure 3. Structures of anticancer phenolic compounds reported from plants available in Ethiopia.](image-url)

**Figure 3.** Structures of anticancer phenolic compounds reported from plants available in Ethiopia.
Table 3. Phenolic compounds isolated from medicinal plants that are traditionally used to treat cancer in Ethiopia.

| Plant                  | Class of Compounds | Cell Lines | IC_{50}          | Pharmacology                        | Isolated Active Compounds                                      | Reference |
|------------------------|--------------------|------------|------------------|-------------------------------------|-----------------------------------------------------------------|-----------|
| *Maytenus senegalensis* (Celastraceae) | Phenolic          | L5178Y     | 10 µg/mL (100% inhibition) | -                                   | (-) Epigallocatechin (25)                                        | [79]      |
|                        |                    |            |                  |                                     | 5-(1-Methoxyethyl)-1-methylphenanthren-2,7-diol (26)             |           |
|                        |                    | MCF-7      | 10.87 ± 0.82 µM  |                                     | Efususol A (27)                                                 |           |
|                        |                    | HepG-2     | 26.68 ± 2.95 µM  |                                     | Efusol                                                          |           |
|                        |                    | SHSY-5Y    | 22.83 ± 0.98 µM  |                                     | Dehydroefusol                                                   |           |
|                        |                    | HepG-2     | 23.13 ± 1.79 µM  |                                     |                                                                  |           |
|                        | Phenanthrenes      | SMMC-7721  | 25.35 ± 2.08 µM  |                                     |                                                                  |           |
| Juncus effusus L. (Juncaceae) |                  | HepG-2     | 12.43 ± 0.41 µM  |                                     | Dehydroefusol                                                   | [80]      |
|                        |                    | Hela       | 13.07 ± 2.56 µM  |                                     |                                                                  |           |
|                        |                    | HepG-2     | 26.04 ± 4.49 µM  |                                     |                                                                  |           |
|                        |                    | Hela       | 16.35 ± 6.04 µM  |                                     |                                                                  |           |
|                        |                    |            | 29.63 ± 0.67 µM  |                                     |                                                                  |           |
|                        |                    | HepG-2     | 16.45 ± 1.12 µM  |                                     |                                                                  |           |
|                        |                    | Hela       | 15.17 ± 2.47 µM  |                                     |                                                                  |           |
|                        |                    | MCF-7      | 27.10 ± 1.17 µM  |                                     |                                                                  |           |
|                        | 9,10-Dihydrophenanthrene | HT22      | 100 µM           | Caspase-3-mediated cytotoxicity     | Efususol A (27)                                                 | [81]      |
|                        |                    |            |                  |                                     | 1-Methylpyrene-2,7-diol                                          |           |
|                        |                    |            |                  |                                     |                                                                  |           |
| Plumbago zeylanica     | Naphthoquinones   | A549       | 10.3 µM          |                                     | Apoptosis                                                       | [82]      |
|                        |                    | H292       | 7.3 µM           |                                     | Plumbagin (28)                                                  |           |
|                        |                    | H460       | 6.1 µM           |                                     |                                                                  |           |
|                        |                    | Panc-1     | 2.1 µM           |                                     |                                                                  |           |
| Kniphofia foliosa *Hochst* | Phenylanthraquinones | B16       | 3.3 ± 0.39 µM    | Necrotic cell death                | Knipholone (29)                                                 | [15]      |
|                        |                    | RAW 264.7  | 1.6 ± 0.25 µM    |                                     |                                                                  |           |
|                        |                    | U937       | 0.5 ± 0.05 µM    |                                     |                                                                  |           |
|                        |                    | THP-1      | 0.9 ± 0.09 µM    |                                     |                                                                  |           |

Cell lines: SMMC-7721 = Human hepatocarcinoma, L5178Y = Mouse lymphoma, SHSY-5Y = human neuroblastoma, MCF-7 = Human breast adenocarcinoma, SMMC-7721 = Human hepatocarcinoma, HepG2 = Liver hepatocarcinoma, Hela = Human cervical cancer, HT22 = mouse hippocampal neuronal, B16 = mouse melanoma, RAW 264.7 = mouse macrophage tumor, THP-1 = human acute monocytic leukaemic, U937 = promonocytic leukaemic, IC_{50} = Concentration that inhibited cell proliferation by 50%. * Plant material collected from Ethiopia.
3.3. Alkaloids

Vinblastine (30) and vincristine (31) (Figure 4) are one of the most effective bis-indole vinca alkaloids as anticancer drugs, isolated from the leaves of *Catharanthus roseus* [84]. This is one of the most precious anticancer plants indigenous to Madagascar. Previously, approximately 30 bis-indole alkaloids and over 60 monomeric indole alkaloids have been isolated from the aerial parts and roots of *C. roseus* [85,86]. Wang et al. [87] isolated three new cytotoxic dimeric indole alkaloids (32–34) along with other five known compounds from the whole plant of *C. roseus* collected from China (Table 4). Among the isolated compounds, leurosine (36) showed the most potent cytotoxic activity with IC\textsubscript{50} value of $0.73 \pm 0.06 \text{µM}$. Furthermore, the isolated three new compounds (32–34) also showed potent cytotoxicity against triple-negative breast cancer (MDA-MB-231) cell line with IC\textsubscript{50} values ranging from $0.97 \pm 0.07 \text{µM}$ to $7.93 \pm 0.42 \text{µM}$. Another alkaloid, cathachunine (40), also showed a promising cytotoxic activity against HL-60 by inducing an intrinsic apoptotic pathway [88]. On the other hand, the monoterpenoid indole alkaloids vindoline and catharanthine, isolated from Malaysian *V. roseus*, showed weak cytotoxic activity against HCT 116 [89]. Furthermore, colchicine (41), isolated from the seeds of *Gloriosa superba*, demonstrated moderate activity against six human cancer cell lines (A549, MCF-7, MDA-MB231, PANC-1, HCT116, and SiHa) [90].

![Figure 4. Structures of anticancer alkaloids reported from plants present in Ethiopia.](image)

**Figure 4.** Structures of anticancer alkaloids reported from plants present in Ethiopia.
Table 4. Alkaloids isolated from medicinal plants that are traditionally used to treat cancer in Ethiopia.

| Plants                          | Class of Compounds | Cell Lines      | IC_{50} Values | Pharmacology                              | Isolated Active Compounds               | Reference |
|---------------------------------|--------------------|-----------------|----------------|-------------------------------------------|-----------------------------------------|-----------|
| Catharanthus roseus (L.)        | Bisindole alkaloid | SH-SY5Y         | 0.1 µM         | Mitotic arrest and apoptosis              | Vincristine (31)                        | [91]      |
| G. Don (Apocynaceae)            |                    | MDA-MB-231      | 0.67 ± 0.03 nM |                                            | Vinblastine (30)                        |           |
|                                 |                    |                 | 0.97 ± 0.07 µM |                                            | 14′,15′-Didehydrocyclovinblastine (32) |           |
|                                 |                    |                 | 7.93 ± 0.42 µM |                                            | 17-Deacetylcyclovinblastine (33)        |           |
|                                 |                    |                 | 3.55 ± 0.19 µM |                                            |                                        | [87]      |
|                                 | Indole alkaloids   |                 | 10.67 ± 0.63 µM|                                            |                                        |           |
|                                 |                    |                 | 0.73 ± 0.06 µM |                                            |                                        |           |
|                                 |                    |                 | 8.59 ± 0.51 µM |                                            |                                        |           |
|                                 |                    |                 | 1.11 ± 0.07 µM |                                            |                                        |           |
|                                 |                    |                 | 4.26 ± 0.23 µM |                                            |                                        |           |
|                                 |                    | HCT 116         | >200 µg/mL     | Induction of apoptosis via an intrinsic pathway | Cathachunine (40)                      | [88]      |
|                                 |                    |                 | 60 µg/mL       |                                            |                                        |           |
|                                 | Bisindole alkaloid | HL-60           | 9.1 ± 0.7 µM   | G2/M phase arrest                          | Colchicine (41)                         | [90]      |
| Gloriosa superba (Colchicaceae) | Alkaloid           | A-549 and MDA-MB-231 | 60 nM         |                                            |                                        |           |
|                                  | Steroidal glycoalkaloids | MGC-803     | 5.2 µg/mL      | Apoptosis                                  |                                        |           |
| Solarum nigrum (Solanaceae)     | MGC-803            |                 | 26.5 µg/mL     |                                            |                                        |           |
|                                  | Steroidal glycoalkaloids | MGC-803      | 8.77 µg/mL     |                                            | β1-Solasonine                           | [92]      |
|                                  |                     |                 | 20.1 µg/mL     |                                            | Solamargine (43)                        |           |

Cell lines: MDA MB 231 = Triple-negative breast cancer, SW480 = Human colorectal, HCT116 = Human colorectal carcinoma, HL60 = Human promyelocytic leukemia, MCF-7 = Human breast adenocarcinoma, SMMC-7721 = Human hepatocarcinoma, A-549 = Human lung adenocarcinoma, MGC-803 = Human gastric cancer. IC_{50} = Concentration that inhibited cell proliferation by 50%.
3.4. Steroids and Lignans

Steroids and lignans, in addition to other phytochemicals, are common secondary metabolites reported from Ethiopian plants. Evidence and epidemiological studies suggest that phytosterols and lignans are protective against a wide range of diseases and possess anticancer activity [93]. Withanolides are cytotoxic steroidal lactones, reported from various plants of the family Solanaceae [94], of which withaferine-A (44) and 5β,6β,14α,15α-diepoxy-4β,27-dihydroxy-1-oxowitha-2,24-dienolide (45) (Figure 5), isolated from Withania somnifera, demonstrated anticancer activity against human lung cancer cell line (NCI-H460) with IC₅₀ values of 0.45 ± 0.00 and 8.3 ± 0.21 µg/mL, respectively [94]. Several buffadinolides, cardiac glycosides with steroidal nucleus, including berscillogenin, 3-epiberscillogenin, and bersenogenin [95]; hellebrigenin 3-acetate (48); and hellebrigenin 3,5-diacetate (49) [96] isolated from Bersama abyssinica collected from Ethiopia, demonstrated cytotoxic activities. β-Sitosterol-3-O-glucoside, a phytosterol from Prunus Africana, exhibited poor anticancer activity against three cell lines (Table 5).

Lignans and isoflavonoids are the major classes of phytoestrogens [97] which showed potential anticancer activity against various cells. Three lignans, namely, (−)-carinol (50), (−)-carissanol (51), and (−)-nortrachelogenin, isolated from Carissa spinarum, were found to be cytotoxic against A549, MCF-7, and WI-38 cell lines. Among these, (−)-carinol (i.e., a compound with butanediol structure) showed more potent cytotoxic activity against these three cell lines with IC₅₀ value of 1 µg/mL, as compared to (−)-carissanol and (−)-nortrachelogenin [98]. Secoisolariciresinol (52) and matairesinolic (53), two lignans isolated from Linum usitatissimum, exhibited cytotoxicity against MCF-7 cells with IC₅₀ values of 10 and 1 µM, respectively [99].
### Table 5. Steroidal and Lignan compounds isolated from medicinal plants that are traditionally used to treat cancer in Ethiopia.

| Plant                              | Class of Compounds | Cell Lines          | IC₅₀            | Isolated Active Compounds                                      | Reference |
|-----------------------------------|--------------------|---------------------|-----------------|---------------------------------------------------------------|-----------|
| *Prunus africana* (Hook.f.) Kalkman (Rosaceae) | Steroids           | HEK293             | 937 µg/mL       | β-Sitosterol-3-O-glucoside                                    | [93]      |
|                                   |                    | HepG2              | 251 µg/mL       |                                                               |           |
|                                   |                    | Caco-2             | 54 µg/mL        |                                                               |           |
| *Withania somnifera* (Solanaceae)  | Steroidal lactone  | NCI-H460           | 0.45 ± 0.00 µg/mL | Withaferin A (44)                                             | [94]      |
|                                   |                    |                    | 8.3 ± 0.12 µg/mL | 5β,6β,14α,15α-Diepoxy-4β,27-dihydroxy-1-oxowitha-2,24-dienolide (45) |           |
|                                   |                    |                    | 95.6 ± 2.60 µg/mL | 27-Acetoxy-4β,6α-dihydroxy-5β-chloro-1-oxowitha-2,24-dienolide (46) |           |
| *Withasteroid*                    |                    | MCF-7 and WRL-68   | 1.0 µg/mL       | 5,6-De-epoxy-5-en-7-one-17-hydroxy withaferin A (47)          | [100]     |
|                                   |                    | Caco-2             | 3.4 µg/mL       |                                                               |           |
|                                   |                    | PC-3               | 7.4 µg/mL       |                                                               |           |
| *Bersama abyssinica* Fresen.* (Melianthaceae) | Steroids (bufadienolide) | KB              | 0.62 µg/mL (ED₅₀) | Bersillogenin                                                  | [95]      |
|                                   |                    |                    | 0.0046 µg/mL (ED₅₀) | 3-Epibersillogenin                                             |           |
|                                   |                    |                    | 10⁻⁷ µg/mL (ED₃₀) | Bersenogenin                                                   |           |
|                                   |                    |                    | 10⁻³ µg/mL (ED₅₀) | Hellebrigenin 3-acetate                                        | [96]      |
|                                   |                    |                    |                 | Hellebrigenin 3,5-diacetate                                    |           |
| *Carissa spinarum* (Apocynaceae)  | Lignans            | A549               | <1 µg/mL        | (−)-Carinol (50)                                              |           |
|                                   |                    | MCF-7              |                 |                                                               |           |
|                                   |                    | WI-38              |                 |                                                               |           |
|                                   |                    | A549               | 11.0 µg/mL      | (−)-Carissanol (51)                                           | [98]      |
|                                   |                    | MCF-7              | 17.4 µg/mL      |                                                               |           |
|                                   |                    | WI-38              | 6.2 µg/mL       |                                                               |           |
|                                   |                    | A549               | 29.0 µg/mL      | (−)-Nortrachelogenin                                          |           |
|                                   |                    | MCF-7              | 88.3 µg/mL      |                                                               |           |
| *Linum usitatissimum* (Linaceae)  | Lignans            | MCF-7              | 1 × 10⁻³ mol/L  | Secoisolariciresinol (52)                                     | [99]      |
|                                   |                    | WI-38              | 1 × 10⁻⁶ M      | Matairesinol (53)                                             |           |

Cell lines: HEK293 = Human embryonic kidney, HepG2 = Liver hepatocarcinoma, Caco-2 = Human colon carcinoma, NCI-H460 = Human large-cell lung carcinoma, MCF-7 = Human breast adenocarcinoma, WRL-68 = Human hepatic, PC-3 = Human prostate cancer, KB = Human mouth epidermal carcinoma, MGC-803 = Human gastric cancer, A-549 = Human lung adenocarcinoma, WI-38 = Normal human embryonic, IC₅₀ = Concentration that inhibited cell proliferation by 50%. ED₅₀ = Effective dose for 50% of the population * Plant material collected from Ethiopia.
4. Preclinical, In Vivo, and Clinical Studies on Ethiopian Anticancer Plants

Preclinical studies generate data on the efficacy, safety, and pharmacokinetic properties of lead compounds, which will later be used to select better molecules for clinical trials. Assessment of the findings of preclinical in vivo animal studies supports the traditional use of plants to manage cancer in Ethiopia (Table 6). Despite the preclinical efficacy data, there are no clinically significant anticancer agents isolated from traditionally used Ethiopian plants. Moreover, there are also no clinical trials conducted on anticancer plants that are collected from Ethiopia. Among reviewed phytochemicals only ursolic acid, secoisolariciresinol (52), and colchicines (41), isolated from plants collected elsewhere, were considered further for clinical trial.

Figure 5. Structures of anticancer steroids and lignans reported from plants available in Ethiopia.
Table 6. Animal efficacy studies, clinical trials, and/or clinically approved agents among Ethiopian anticancer plants/compounds.

| Plants                  | Crude Extract   | Isolated Compounds                  | In Vivo Studies                                                                 | Clinical Trials (Status)                        | Clinically Approved for                                                                 |
|-------------------------|-----------------|-------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------------------------------------------------------|
| **Bersama abyssinica**  |                 | Hellebrigenin 3-acetate (48)        | Significantly inhibits Walker intramuscular carcinosarcoma 256 in rats [96]      | -                                             | -                                                                                        |
|                        | Ethanollic extract |                                   | Significantly increased the life span and decreased the tumor volume in Ehrlich ascites carcinoma-bearing mice [101] | -                                             | -                                                                                        |
| **Catharanthus roseus** |                 | Vincristine (31)                    | -                                                                               | -                                             | Childhood leukaemia, Hodgkin’s disease and acute panmyelosis [102]                        |
|                         |                 | Vinblastine (30)                    | -                                                                               | -                                             | Lymphosarcoma, choriocarcinoma, neuroblastoma and lymphocytic leukemia [103]              |
| **Euphorbia tirucalli** |                 | Hydroalcoholic extract              | Significantly reduced tumor growth in Ehrlich ascites tumor-bearing mice [104]  | -                                             | -                                                                                        |
|                         | Latex           |                                     | Significantly reduced tumor growth and cachexia in Walker 256 tumor-bearing rats [105] | -                                             | -                                                                                        |
| **Gloriosa superba**    |                 | Ethanollic crude extract            | Significantly reduced tumor growth in combination with gemcitabine in a murine model of pancreatic adenocarcinoma [106] | -                                             | -                                                                                        |
|                         |                 | Colchicine (41)                     | -                                                                               | Phase II for castrate resistant prostate cancer (Withdrawn due to funding) [107] | -                                                                                        |
| **Jatropha curcas**     | Methanolic fractions |                             | Showed significant anti-metastatic and antiproliferative activity in C57BL/6 mice [108] | -                                             | -                                                                                        |
| **Linum usitatissimum** |                 | Secoisolariciresinol (52)           | -                                                                               | Phase II (Completed) [109]                     | -                                                                                        |
| Plants                  | Crude Extract  | Isolated Compounds | In Vivo Studies                                                                                          | Clinical Trials (Status) | Clinically Approved for |
|------------------------|----------------|--------------------|---------------------------------------------------------------------------------------------------------|--------------------------|-------------------------|
| *Prunus Africana*      | Ethanol extract| Showed significant reduction in prostate cancer incidence in mice [110]                                  | -                                                                       | Early Phase I [111]     | -                      |
|                        | Ursolic Acid   | -                  |                                                                                                         |                          |                         |
| *Plumbago zeylanica L.*| Plumbagin      | Significantly inhibits squamous cell carcinomas in FVB/N mice [112]                                      | -                                                                       | -                        | -                      |
| *Ricinus communis*     | Fruit extract  | Significantly reduced tumor volume in 4T1 syngeneic mouse model [113]                                     | -                                                                       | -                        | -                      |
| *Solanum nigrum*       | Crude polysaccharides | Significant growth inhibition in cervical cancer tumor-bearing mice [114]                                  | -                                                                       | -                        | -                      |
|                        | Aqueous extract | Significantly inhibits early hepatocarcinogenesis [115]                                                  | -                                                                       | -                        | -                      |
| *Vernonia amygdalina*  | Aqueous crude extract | Increase efficacies and optimizes treatment outcomes when given with paclitaxel in athymic mice [116]   | -                                                                       | -                        | -                      |
| *Vernonia hymenolepis* | Vernolepin     | Significantly inhibited intramuscular carcinosarcoma in walker tumor bearing rats [117]                   | -                                                                       | -                        | -                      |
|                        | Aqueous extract | Decreased tumor volume in orthotopic glioma allograft rat model [118]                                     | -                                                                       | -                        | -                      |
| *Withania somnifera*   | Ethanolic extract | Significantly improve colon cancer treatment in mice [119]                                              | -                                                                       | -                        | -                      |
|                        | Withalerin A   | Significantly inhibited HepG2-xenografts and diethylnitrosamine (DEN)-induced-hepatocellular carcinoma (HCC) in C57BL/6 mice [120] | -                                                                       | -                        | -                      |
5. Conclusions

Despite the traditional use of various Ethiopian plants for the treatment of cancer by herbal medicine practitioners for many decades, only a few active anticancer crude extracts, herbal preparations, and pure compounds were tested and so far no clinical trial was conducted on them. In this review, an attempt has been made to document antiproliferative, antitumor, and cytotoxic natural products small molecules isolated from medicinal plants that are traditionally used to treat cancer in Ethiopia. However, among the reported active compounds, only few have been isolated from plants that are originated and collected from Ethiopian geographic location, despite their wider presence and traditional claim at home. The majority of compounds reported in this review are isolated from plants (corresponding to Ethiopian species) that were collected from different regions of the world. However, the comprehensive list of active compounds (IC₅₀ and ED₅₀ values) provided in this review will help to identify the most potent source(s) of these compounds, as bioactive marker(s), of local flora. Based on the higher frequency of citation Croton macrostachyus, Jatropha curcas, Plumbago zeylanica, and Vernonia hymenolepis are potential candidates for follow-up bioassay guided investigations. Furthermore, plants with reported antiproliferative compounds such as Podocarpus falcatus, Linum usitatissimum, and Zehneria scabra should also be examined for additional cytotoxic compounds and evaluated against a battery of cancer cell lines.

Generally, the ecological variation has a huge impact on the biosynthesis, yield of active constituent and biological potency of secondary metabolites produced by plants of similar species from different geographical regions. Thus, Ethiopian anticancer plants might have novel active constituents to fight cancer, based on traditional medical use, than those collected from other regions due to their unique geographical location and inherent climatic condition of the diverse landscape. Unfortunately, these valuable plant resources are disappearing rapidly due to climate change, rapid urbanization, agricultural land expansion, and artificial deforestation; therefore, Ethiopian flora is facing a great challenge, and thus it is high time to examine the anticancer plants systematically with the aim to carry out chemical and biological investigations, as well as clinical trials on promising anticancer plant extracts based on ethnopharmacological knowledge.

**Author Contributions:** I.M., K.A., S.T. and E.L.; developed the concept, analyzed the data, and wrote the manuscript. Y.A., M.K. and E.T.; performed the literature searches, and contributed to draft the manuscript. All authors have read and agreed to the published version of this manuscript.

**Funding:** This research received no external funding.

**Acknowledgments:** M.K. and I.M. would like to thanks NCNPR, University of Mississippi, for technical support in preparing the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]

2. Cragg, G.M.; Pezzuto, J.M. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med. Princ. Pract. 2016, 25, 41–59. [CrossRef] [PubMed]

3. Rishton, G.M. Natural products as a robust source of new drugs and drug leads: Past successes and present day issues. Am. J. Cardiol. 2008, 101, S43–S49. [CrossRef] [PubMed]

4. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016, 79, 629–661. [CrossRef] [PubMed]

5. Kelbessa, E.; Demissew, S. Diversity of vascular plant taxa of the flora of Ethiopia and Eritrea. Ethiop. J. Biol. Sci. 2014, 13, 37–45.

6. Tuasha, N.; Petros, B.; Asfaw, Z. Medicinal plants used by traditional healers to treat malignancies and other human ailments in Dalle District, Sidama Zone, Ethiopia. J. Ethnobiol. Ethnomed. 2018, 14, 1–21. [CrossRef]
7. Bussa, N.F.; Belayneh, A. Traditional medicinal plants used to treat cancer, tumors and inflammatory ailments in Harari Region, Eastern Ethiopia. S. Afr. J. Bot. 2019, 122, 360–368. [CrossRef]

8. Attalbachew, M.; Chandravanshi, B.S.; Redi, M. Selected secondary metabolites and antioxidant activity of khat (Catha edulis Forsk) chewing leaves extract. Int. J. Food Prop. 2014, 17, 45–64. [CrossRef]

9. Worku, N.; Mossie, A.; Stich, A.; Daugschies, A.; Trettner, S.; Hemdan, N.Y.; Birkenmeier, G. Evaluation of the in vitro efficacy of Artemisia annua, Rumex abyssinicus, and Catha edulis Forsk extracts in cancer and Trypanosoma brucei cells. ISRN Biochem. 2013, 1, 1–10. [CrossRef]

10. Tauchen, J.; Doskoci, I.; Caffi, C.; Lulekal, E.; Marsik, P.; Havlik, J.; Van Damme, P.; Koskoska, L. In vitro antioxidant and anti-proliferative activity of Ethiopian medicinal plant extracts. Ind. Crops Prod. 2015, 74, 671–679. [CrossRef]

11. Yeshak, M.Y.; Burman, R.; Asres, K.; Göransson, U. Cyclotides from an extreme habitat: Characterization of cyclic peptides from Viola abyssinica of the Ethiopian highlands. J. Nat. Prod. 2011, 74, 727–731. [CrossRef] [PubMed]

12. Nibret, E.; Youns, M.; Krauth-Siegel, R.L.; Wink, M. Biological activities of xanthatin from Xanthium strumarium leaves. Phytother. Res. 2011, 25, 1883–1890. [CrossRef] [PubMed]

13. Gebrelibanos, M.; Asres, K.; Veeresham, C. In Vitro radical scavenging activity of the leaf and bark extracts of Senna singueana (Del.) Lock. Ethiop. Pharm. J. 2007, 25, 77–84. [CrossRef]

14. Mengesha, A.E.; Youan, B.-B.C. Anticancer activity and nutritional value of extracts of the seed of Glinus lotoides. J. Nutr. Sci. Vitaminol. 2010, 56, 311–318. [CrossRef] [PubMed]

15. Habtemariam, S. Knipholone anthrone from Kniphofia foliosa induces a rapid onset of necrotic cell death in cancer cells. Fitoterapia 2010, 81, 1013–1019. [CrossRef]

16. Tuasha, N.; Hailemeskel, E.; Erko, B.; Petros, B. Comorbidity of intestinal helminthiases among malaria outpatients of Wondo Genet health centers, southern Ethiopia: Implications for integrated control. BMC Infect. Dis. 2019, 19, 659. [CrossRef]

17. Esubalew, S.T.; Belete, A.; Lulekal, E.; Gabriel, T.; Engidawork, E.; Asres, K. Review of ethnobotanical and ethnopharmacological evidences of some ethiopian medicinal plants traditionally used for the treatment of cancer. Ethiop. J. Health Dev. 2017, 31, 161–187.

18. Friis, I.; Demissew, S.; Van Breugel, P. Atlas of the potential vegetation of Ethiopia. In Det Kongelige Danske Videnskabernes Selskab; Nabu Press: Charleston, SC, USA, 2010.

19. Makonnen, E.; Hagos, E. Antispasmodic effect of Bersama abyssinica aqueous extract on guinea-pig ileum. Phytother. Res. 1993, 7, 211–212. [CrossRef]

20. Birhanu, Z. Traditional use of medicinal plants by the ethnic groups of Gondar Zuria District, North-Western Ethiopia. J. Nat. Rem. 2013, 13, 46–53.

21. Tesfaye, S.; Belete, A.; Engidawork, E.; Gedif, T.; Asres, K. Ethnobotanical study of medicinal plants used by traditional healers to treat cancer-like symptoms in eleven districts, Ethiopia. Evid-Based Compl. Alt. 2020, 2020, 1–23. [CrossRef]

22. Agize, M.; Demissew, S.; Asfaw, Z. Ethnobotany of medicinal plants in Loma and Gena bosa districts (woredas) of dawro zone, southern Ethiopia. Topcls. J. Herb. Med. 2013, 2, 194–212.

23. Giday, M.; Asfaw, Z.; Woldu, Z. Ethnomedicinal study of plants used by Sheko ethnic group of Ethiopia. J. Ethnopharmacol. 2010, 132, 75–85. [CrossRef] [PubMed]

24. Kidane, B.; van Andel, T.; van der Maesen, L.J.G.; Asfaw, Z. Use and management of traditional medicinal plants by Maale and Ari ethnic communities in southern Ethiopia. J. Ethnobiol. Ethnomed. 2010, 6, 81. [CrossRef]

25. Regassa, R. Assessment of indigenous knowledge of medicinal plant practice and mode of service delivery in Hawassa city, southern Ethiopia. J. Med. Plants Res. 2013, 7, 517–535.
29. Kewessa, G.; Abebe, T.; Demessie, A. Indigenous knowledge on the use and management of medicinal trees and shrubs in Dale District, Sidama Zone, Southern Ethiopia. *Ethnobot. Res. Appl.* 2015, 14, 171–182. [CrossRef]

30. Abebe, W. A survey of prescriptions used in traditional medicine in Gondar region, northwestern Ethiopia: General pharmaceutical practice. *J. Ethnopharmacol.* 1986, 18, 147–165. [CrossRef]

31. Teklehaymanot, T.; Giday, M. Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia. *J. Ethnobiol. Ethnomed.* 2007, 3, 1–11. [CrossRef]

32. Birhanu, Z.; Endale, A.; Shewamene, Z. An ethnomedicinal investigation of plants used by traditional healers of Gondar town, North-Western Ethiopia. *J. Med. Plants Stud.* 2015, 3, 36–43.

33. Chekole, G.; Asfaw, Z.; Kelbessa, E. Ethnobotanical study of medicinal plants in the environs of Tara-gedam and Amba remnant forests of Libo Kemkem District, northwest Ethiopia. *J. Ethnobiol. Ethnomed.* 2015, 11, 1–38. [CrossRef] [PubMed]

34. Teklehaymanot, T. Ethnobotanical study of knowledge and medicinal plants used by the people in Dek Island in Ethiopia. *J. Ethnopharmacol.* 2009, 124, 69–78. [CrossRef] [PubMed]

35. Yineger, H.; Yewhalaw, D. Traditional medicinal plant knowledge and use by local healers in Sekoru District, Jimma Zone, Southwestern Ethiopia. *J. Ethnobiol. Ethnomed.* 2007, 3, 1–7. [CrossRef] [PubMed]

36. Kebede, A.; Ayalew, S.; Mesfin, A.; Mululem, G. Ethnobotanical investigation of traditional medicinal plants commercialized in the markets of Dire Dawa city, eastern Ethiopia. *J. Med. Plants Stud.* 2016, 4, 170–178.

37. Ayele, T.T. A Review on traditionally used medicinal plants/herbs for cancer therapy in Ethiopia: Current status, challenge and future perspectives. *Org. Chem. Curr. Res.* 2018, 7. [CrossRef]

38. Tolossa, K.; Debela, E.; Athanasiadou, S.; Tolera, A.; Ganga, G.; Houdijk, J.G. Ethno-medicinal study of plants used for treatment of human and livestock ailments by traditional healers in South Omo, Southern Ethiopia. *J. Ethnobiol. Ethnomed.* 2013, 9, 1–15. [CrossRef]

39. Bekele, G.; Reddy, P.R. Ethnobotanical study of medicinal plants used to treat human ailments by Guji Oromo tribes in Abaya District, Borana, Oromia, Ethiopia. *Univers. J. Plant Sci.* 2015, 3, 1–8. [CrossRef]

40. Abera, B. Medicinal plants used in traditional medicine in Jimma Zone, Southwest Ethiopia. *Ethiop. J. Health Sci.* 2003, 13, 85–94.

41. Wabe, N.; Mohammed, M.A.; Raju, N.J. An ethnobotanical survey of medicinal plants in the Southeast Ethiopia used in traditional medicine. *Spatula DD* 2011, 1, 153–158. [CrossRef]

42. Zenebe, G.; Zerihun, M.; Solomon, Z. An ethnobotanical study of medicinal plants in Asgede Tsimbila district, Northwestern Tigray, northern Ethiopia. *Ethnobot. Res. Appl.* 2012, 10, 305–320. [CrossRef]

43. Teklay, A.; Abera, B.; Giday, M. An ethnobotanical study of medicinal plants used in Kilte Awulaelo District, Tigray Region of Ethiopia. *J. Ethnobiol. Ethnomed.* 2013, 9, 1–23. [CrossRef] [PubMed]

44. Yadav, R.H. Medicinal plants in folk medicine system of Ethiopia. *J. Poisonous Med. Plants Res.* 2013, 1, 7–11.

45. Yohannis, S.W.; Asfaw, Z.; Kelbessa, E. Ethnobotanical study of medicinal plants used by local people in menz gera midir district, north shewa zone, amhara regional state, Ethiopia. *J. Med. Plants Res.* 2018, 12, 296–314. [CrossRef]

46. Birhanu, A.; Ayalew, S. Indigenous knowledge on medicinal plants used in and around Robe Town, Bale Zone, Oromia Region, South Ethiopia. *J. Med. Plants Res.* 2018, 12, 194–202. [CrossRef]

47. GebyeYehu, G.; Asfaw, Z.; Enyew, A. An ethnobotanical study of traditional use of medicinal plants and their conservation status in Mecha Wereda, west Gojjam zone of Amhara region, Ethiopia. *Int. J. Pharm. Health Care Res.* 2014, 2, 137–154.

48. Yineger, H.; Yewhalaw, D.; Teketay, D. Ethnomedicinal plant knowledge and practice of the Oromo ethnic group in southwestern Ethiopia. *J. Ethnobiol. Ethnomed.* 2008, 4, 1–11. [CrossRef]

49. Demissew, S. A description of some essential oil bearing plants in Ethiopia and their indigenous uses. *J. Essent. Oil Res.* 1993, 5, 465–479. [CrossRef]

50. Agisho, H.; Osie, M.; Lambore, T. Traditional medicinal plants utilization, management and threats in Hadiya zone, Ethiopia. *J. Med. Plant* 2014, 2, 94–108.

51. Giday, M.; Asfaw, Z.; Welde, Z. Medicinal plants of the Meinit ethnic group of Ethiopia: An ethnobotanical study. *J. Ethnopharmacol.* 2009, 124, 513–521. [CrossRef]

52. Birhanu, T.; Abera, D.; Ejeta, E.; Nekemte, E. Ethnobotanical study of medicinal plants in selected Horro Gudurru Woredas, western Ethiopia. *J. Biol. Agric. Healthc.* 2015, 5, 83–93.
53. Gidey, M.; Beyene, T.; Signorini, M.A.; Bruschi, P.; Yirga, G. Traditional medicinal plants used by Kunama ethnic group in Northern Ethiopia. J. Med. Plants Res. 2015, 9, 494–509.
54. Giday, M.; Asfaw, Z.; Elmqvist, T.; Woldu, Z. An ethnobotanical study of medicinal plants used by the Zay people in Ethiopia. J. Med. Plants Res. 2015, 9, 494–509. [CrossRef]
55. Ragunathan, M.; Abay, S.M. Ethnomedicinal survey of folk drugs used in Bahirdar Zuria district, northwestern Ethiopia. Indian J. Tradit. Knowl. 2009, 8, 281–284.
56. Mekuanent, T.; Zebene, A.; Solomon, Z. Ethnobotanical study of medicinal plants in Chilga district, northwestern Ethiopia. J. Nat. Remedies 2015, 15, 88–112. [CrossRef]
57. Habtemariam, S. Cytotoxicity of diterpenes from Premna schimperi and Premna oligotricha. Planta Med. 1995, 61, 368–369. [CrossRef]
58. Connolly, J.D.; Hill, R.A. Triterpenoids. Nat. Prod. Rep. 1994; Volume 2.
59. Hordyjewska, A.; Ostapiuk, A.; Horecka, A. Betulin and betulinic acid in cancer research. J. Pre Clin. Clin. Res. 2018, 12, 72–75. [CrossRef]
60. Chudzik, M.; Korzönek-Szlacheta, I.; Król, W. Triterpenes as potentially cytotoxic compounds. Molecules 2015, 20, 1610–1625. [CrossRef]
61. Phillips, D.R.; Rasbery, J.M.; Bartel, B.; Matsuda, S.P. Biosynthetic diversity in plant triterpene cyclization. Curr. Opin. Plant Biol. 2006, 9, 305–314. [CrossRef]
62. Petronelli, A.; Pannitteri, G.; Testa, U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009, 20, 880–892. [CrossRef] [PubMed]
63. Addo, E.M.; Chai, H.-B.; Hymete, A.; Yeshak, M.Y.; Slebodnick, C.; Kingston, D.G.; Rakotondraibe, L.H. Antiproliferative constitutives of the roots of Ethiopian Podocarpus falcatus and structure revision of 2α-hydroxyxynaglactone F and naglactone I. J. Nat. Prod. 2015, 78, 827–835. [CrossRef] [PubMed]
64. Kongue, M.D.; Talontsi, F.M.; Lamshöft, M.; Kenla, T.J.; Dittrich, B.; Kapche, G.D.; Spiteller, M. Sonhafouonic pathway. Food Chem. Toxicol. 2012, 50, 4333–4339. [CrossRef]
65. Silva, V.A.O.; Rosa, M.N.; Tansini, A.; Oliveira, R.J.; Martinho, O.; Lima, J.P.; Pianowski, L.F.; Reis, R.M. In vitro screening of cytotoxic activity of euphol from Euphorbia tirucalli on a large panel of human cancer-derived cell lines. Exp. Ther. Med. 2018, 16, 557–566. [CrossRef]
66. Reyes-Zurita, F.J.; Rufino-Palomares, E.E.; Lupiñez, J.A.; Cascante, M. Maslinic acid, a natural triterpene from Olea europaea L., induces apoptosis in HT29 human colon-cancer cells via the mitochondrial apoptotic pathway. Cancer Lett. 2009, 273, 44–54. [CrossRef]
67. Darmanin, S.; Wismayer, P.S.; Camilleri Podesta, M.T.; Micallef, M.J.; Buhagiar, J.A. An extract from Ricinus communis L. leaves possesses cytotoxic properties and induces apoptosis in SK-MEL-28 human melanoma cells. Nat. Prod. Res. 2009, 23, 561–571. [CrossRef]
68. Burkill, H.M. The Useful Plants of West Tropical Africa. Families E–I.; Royal Botanic Gardens: Richmond, UK, 1994; Volume 2.
69. Liu, J.-Q.; Yang, Y.-F.; Li, X.-Y.; Liu, E.-Q.; Li, Z.-R.; Zhou, L.; Li, Y.; Qiu, M.-H. Cytotoxicity of naturally occurring rhamnofolane diterpenes from Jatropha curcas. Phytochemistry 2013, 96, 265–272. [CrossRef]
70. Zhang, X.-Q.; Li, F.; Zhao, Z.-G.; Liu, X.-L.; Tang, Y.-X.; Wang, M.-K. Diterpenoids from the root bark of Jatropha curcas and their cytotoxic activities. Phytochem. Lett. 2012, 5, 721–724. [CrossRef]
75. Tang, X.-L.; Yang, X.-Y.; Jung, H.-J.; Kim, S.-Y.; Jung, S.-Y.; Choi, D.-Y.; Park, W.-C.; Park, H. Asiatic acid induces colon cancer cell growth inhibition and apoptosis through mitochondrial death cascade. *Biol. Pharm. Bull.* 2009, 32, 1399–1405. [CrossRef] [PubMed]

76. Alsayari, A.; Kopel, I.; Ahmed, M.S.; Soliman, H.S.; Annadurai, S.; Halaweish, F.T. Isolation of anticancer constituents from *Cucumis prophetarum* var. *prophetarum* through bioassay-guided fractionation. *BMC Complement. Altern. Med.* 2018, 18, 1–12. [CrossRef] [PubMed]

77. Kupchan, S.M.; Hemingway, R.J.; Karim, A.; Werner, D. Tumor inhibitors. XLVII. *Vernodalin* and *vernomygdin*, two new cytotoxic sesquiterpene lactones from *Vernonia amygdalina* Del. *J. Org. Chem.* 1969, 34, 3908–3911. [CrossRef] [PubMed]

78. Selassie, C.D.; Kapur, S.; Verma, R.P.; Rosario, M. Cellular apoptosis and cytotoxicity of phenolic compounds: A quantitative structure-activity relationship study. *J. Med. Chem.* 2005, 48, 7234–7242. [CrossRef] [PubMed]

79. Okoye, F.B.C.; Debbab, A.; Wray, V.; Esimone, C.O.; Osadebe, P.O.; Proksch, P. A phenyldilactone, bisnorsesquiterpene, and cytotoxic phenolics from *Maytenus senegalensis* leaves. *Tetrahedron Lett.* 2014, 55, 3756–3760. [CrossRef]

80. Ma, W.; Zhang, Y.; Ding, Y.-Y.; Liu, F.; Li, N. Cytotoxic and anti-inflammatory activities of phenanthrenes from the medullae of *Juncus effusus*. *Arch. Pharm. Res.* 2016, 39, 154–160. [CrossRef]

81. Ishiuchi, K.; Kosuge, Y.; Hamagami, H.; Ozaki, M.; Ishige, K.; Ito, Y.; Kitana, S. Chemical constituents isolated from *Juncus effusus* induce cytotoxicity in HT22 cells. *J. Nat. Med.* 2015, 69, 421–426. [CrossRef]

82. Xu, T.-P.; Shen, H.; Liu, L.-X.; Shu, Y.-Q. Plumbagin from *Plumbago Zeylanica* L. Induces Apoptosis in Human Non-small Cell Lung Cancer Cell Lines through NF-κB Inactivation. *Asian Pac. J. Cancer Prev.* 2013, 14, 2323–2331. [CrossRef]

83. Chen, C.-A.; Chang, H.-H.; Kao, C.-Y.; Tsai, T.-H.; Chen, Y.-J. Plumbagin, isolated from *Plumbago zeylanica*, induces cell death through apoptosis in human pancreatic cancer cells. *Pancreatology* 2009, 9, 797–809. [CrossRef] [PubMed]

84. Ruszkowska, J.; Chrobak, R.; Wróbel, J.T.; Czarnocki, Z. Novel bisindole derivatives of *Catharanthus* alkaloids with potential cytotoxic properties. In *Developments in Tryptophan and Serotonin Metabolism*; Springer: Berlin/Heidelberg, Germany, 2003; pp. 643–646.

85. Jossang, A.; Fodor, P.; Bodo, B. A new structural class of bisindole alkaloids from the seeds of *Catharanthus roseus*: Vingramine and methylvingramine. *J. Org. Chem.* 1998, 63, 7162–7167. [CrossRef] [PubMed]

86. Zhang, W.-K.; Xu, J.-K.; Tian, H.-Y.; Wang, L.; Zhang, X.-Q.; Xiao, X.-Z.; Li, P.; Ye, W.-C. Two new vinblastine-type N-oxide alkaloids from *Catharanthus roseus*. *Nat. Prod. Res.* 2013, 27, 1911–1916. [CrossRef]

87. Wang, C.-H.; Wang, G.-C.; Wang, Y.; Zhang, X.-Q.; Huang, X.-J.; Zhang, D.-M.; Chen, M.-F.; Ye, W.-C. Cytotoxic dimeric indole alkaloids from *Catharanthus roseus*. *Fitoterapia* 2012, 83, 765–769. [CrossRef]

88. Wang, X.-D.; Li, C.-Y.; Jiang, M.-M.; Li, D.; Wen, P.; Song, X.; Chen, J.-D.; Guo, L.-X.; Hu, X.-P.; Li, G.-Q. Induction of apoptosis in human leukemia cells through an intrinsic pathway by cathachunine, a unique alkaloid isolated from *Catharanthus roseus*. *Phytomedicine* 2016, 23, 641–653. [CrossRef] [PubMed]

89. Siddiqui, M.J.; Ismail, Z.; Aisha, A.F.A.; Majid, A.M. Cytotoxic activity of *Catharanthus roseus* (Apocynaceae) crude extracts and pure compounds against human colorectal carcinoma cell line. *Int. J. Pharmacol.* 2010, 6, 43–47. [CrossRef]

90. Balkrishna, A.; Das, S.K.; Pokhrel, S.; Joshi, A.; Verma, S.; Sharma, V.K.; Sharma, V.; Sharma, N.; Joshi, C.S. Colchicine: Isolation, LC–MS QToF screening, and anticancer activity study of *Gloriosa superba* seeds. *Molecules* 2019, 24, 2772. [CrossRef]

91. Tu, Y.; Cheng, S.; Zhang, S.; Sun, H.; Xu, Z. Vincristine induces cell cycle arrest and apoptosis in SH-SY5Y human neuroblastoma cells. *Int. J. Mol. Med.* 2013, 31, 113–119. [CrossRef]

92. Ding, X.; Zhu, F.; Yang, Y.; Li, M. Purification, antitumor activity in vitro of steroidal glycoalkaloids from black nightshade (*Solanum nigrum* L.). *Food Chem.* 2013, 141, 1181–1186. [CrossRef]

93. Maiywa, E.; Moodley, R.; Singh, M. Phytochemistry, cytotoxicity and apoptosis studies of β-sitosterol-3-ol and β-amyrin from *Primus africana*. *Afr. J. Tradit. Complement. Altern. Med.* 2016, 13, 105–112. [CrossRef]

94. Choudhary, M.I.; Hussain, S.; Yousuf, S.; Dar, A. Chlorinated and diepoxy withanolides from *Withania somnifera* and their cytotoxic effects against human lung cancer cell line. *Phytochemistry* 2010, 71, 2205–2209. [CrossRef] [PubMed]
95. Kupchan, S.M.; Moniot, J.L.; Sigel, C.W.; Hemingway, R.J. Tumor inhibitors. LXV. Bersenogenin, berscillogenin, and 3-epiberscillogenin, three new cytotoxic bufadienolides from Bersama abyssinica. *J. Org. Chem.* 1971, 36, 2611–2616. [CrossRef][PubMed]

96. Kupchan, S.M.; Hemingway, R.J.; Hemingway, J.C. The isolation and characterization of hellebrigenin 3-acetate and hellebrigenin 3, 5-diacetate, bufadienolide tumor inhibitors from Bersama abyssinica. *Tetrahedron Lett.* 1968, 9, 149–152. [CrossRef]

97. Abarzua, S.; Szewczyk, M.; Gailus, S.; Richter, D.-U.; Roth, W.; Briese, V.; Piechulla, B. Effects of phytoestrogen extracts from *Linum usitatissimum* on the Jeg3 human trophoblast tumour cell line. *Anticancer Res.* 2007, 27, 2053–2058. [PubMed]

98. Wangteeraprasert, R.; Lipipun, V.; Gunaratnam, M.; Neidle, S.; Gibbons, S.; Likhitwitayawud, K. Bioactive compounds from *Carissa spinarum*. *Phytother. Res.* 2012, 26, 1496–1499. [CrossRef]

99. Abarzua, S.; Serikawa, T.; Szewczyk, M.; Richter, D.-U.; Piechulla, B.; Briese, V. Antiproliferative activity of lignans against the breast carcinoma cell lines MCF 7 and BT 20. *Arch. Gynecol. Obstet.* 2012, 285, 1145–1151. [CrossRef]

100. Ali, A.; Joshi, P.; Misra, L.; Sangwan, N.; Darokar, M. 5,6-De-epoxy-5-en-7-one-17-hydroxy withaferin A, a new cytotoxic steroid from *Withania somnifera* L. Dunal leaves. *Nat. Prod. Res.* 2014, 28, 392–398. [CrossRef]

101. Aruna, S.R. In-vitro and in-vivo antitumor activity of *Catharanthus roseus*. Int. *Res. J. Pharm. Appl. Sci.* 2014, 4, 1–4.

102. Moudi, M.; Go, R.; Yien, C.Y.S.; Nazre, M. Vinca alkaloids. *Int. J. Prev. Med.* 2013, 4, 1231–1235.

103. Rai, V.; Tandon, P.K.; Khatoon, S. Effect of chromium on antioxidant potential of *Catharanthus roseus* varieties and production of their anticancer alkaloids: Vinristine and vinblastine. *BioMed Res. Int.* 2014, 1–10. [CrossRef]

104. Valadares, M.C.; Carrucha, S.G.; Accorsi, W.; Queiroz, M.L. *Euphorbia tirucalli* L. modulates myelopoiesis and enhances the resistance of tumour-bearing mice. Int. *Immunopharmacol.* 2006, 6, 294–299. [CrossRef][PubMed]

105. Martins, C.G.; Appel, M.H.; Coutinho, D.S.; Soares, I.P.; Fischer, S.; de Oliveira, B.C.; Fachi, M.M.; Pontarolo, R.; Bonatto, S.J.; Iagher, F. Consumption of latex from *Euphorbia tirucalli* L. promotes a reduction of tumor growth and cachexia, and immunomodulation in Walker 256 tumor-bearing rats. *J. Ethnopharmacol.* 2020, 255, 1–9. [CrossRef][PubMed]

106. Capistrano, I.R.; Vangestel, C.; Vanpachtenbeke, H.; Fransen, E.; Staelens, S.; Apers, S.; Pieters, L. Co-administration of a *Gloriosa superba* extract improves the in vivo antitumoural activity of gemcitabine in a murine pancreatic tumour model. *Phytotherapy Research* 2016, 23, 1434–1440. [CrossRef][PubMed]

107. Drabick, J. Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy; Clinicaltrials Gov. National Library of Medicine: Bethesda, MD, USA, 2013.

108. Balaji, R.; Rekha, N.; Deecaraman, M.; Manikandan, L. Antimetastatic and antiproliferative activity of methanolic fraction of *Jatropha curcas* against B16F10 melanoma induced lung metastasis in C57BL/6 mice. *Afr. J. Pharm. Pharmacol.* 2009, 3, 547–555.

109. Fabian, C.J.; Khan, S.A.; Garber, J.E.; Dooley, W.C.; Yee, L.D.; Klemp, J.R.; Nydegger, J.L.; Powers, K.R.; Kreutzjans, A.L.; Zalles, C.M. Randomized phase IIB trial of the lignan secoisolariciresinol diglucoside in men with prostate cancer who have failed hormone therapy. *Carcinogenesis* 2006, 27, 1145–1151. [CrossRef][PubMed]

110. Shenouda, N.S.; Sakla, M.S.; Newton, L.G.; Besch-Williford, C.; Greenberg, N.M.; MacDonald, R.S.; Lubahn, D.B. Phytosterol *Pygeum africanum* regulates prostate cancer in vitro and in vivo. *Endocrine* 2007, 31, 72–81. [CrossRef]

111. The University of Texas Health Science Center at San Antonio. *Phase I Clinical Trial Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate; Clinicaltrials Gov. National Library of Medicine: Bethesda, MD, USA, 2020.*

112. Sand, J.M.; Hafeez, B.B.; Jamal, M.S.; Witkowsky, O.; Siebers, E.M.; Fischer, J.; Verma, A.K. Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone), isolated from *Plumbago zeylanica*, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. *Carcinogenesis* 2012, 33, 184–190. [CrossRef]
114. Li, J.; Li, Q.; Feng, T.; Zhang, T.; Li, K.; Zhao, R.; Han, Z.; Gao, D. Antitumor activity of crude polysaccharides isolated from *Solanum nigrum* Linne on U14 cervical carcinoma bearing mice. *Phytother. Res.* 2007, 21, 832–840. [CrossRef]

115. Hsu, J.-D.; Kao, S.-H.; Tu, C.-C.; Li, Y.-J.; Wang, C.-J. *Solanum nigrum* L. Extract inhibits 2-Acetylaminofluorene-induced hepatocarcinogenesis through overexpression of Glutathione S-Transferase and antioxidant enzymes. *J. Agric. Food Chem.* 2009, 57, 8628–8634. [CrossRef]

116. Howard, C.B.; Johnson, W.K.; Pervin, S.; Izevbigie, E.B. Recent perspectives on the anticancer properties of aqueous extracts of Nigerian *Vernonia amygdalina*. *Botanics* 2015, 5, 65–76. [CrossRef] [PubMed]

117. Kupchan, S.M.; Hemingway, R.J.; Werner, D.; Karim, A. Tumor inhibitors. XLVI. Vernolepin, a novel sesquiterpene dilactone tumor inhibitor from *Vernonia hymenolepis*. *J. Org. Chem.* 1969, 34, 3903–3908. [CrossRef] [PubMed]

118. Kataria, H.; Kumar, S.; Chaudhary, H.; Kaur, G. *Withania somnifera* Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells. *Mol. Neurobiol.* 2016, 53, 4143–4158. [CrossRef] [PubMed]

119. Muralikrishnan, G.; Dinda, A.K.; Shakeel, F. Immunomodulatory effects of *Withania Somnifera* on Azoxy methane induced experimental colon cancer in mice. *Immunol. Invest.* 2010, 39, 688–698. [CrossRef]

120. Kuppusamy, P.; Nagalingam, A.; Muniraj, N.; Saxena, N.K.; Sharma, D. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice. *Sci. Rep.* 2017, 7, 1–13. [CrossRef]